For science as a whole, 2017 was the best of times and the worst of times. The year saw the approval of three gene therapies, a clinical milestone that has its basis in modern molecular biology.
Experimental drugs are increasingly being tested in combinations from the early stages of drug development, with the rationale that such combination treatments provide added benefit over each single agent by interacting with each other.
More than two-thirds of late-stage breast cancer patients have bone metastases. Those metastases tend to be resistant to chemotherapy, and current treatments often improve bone function and bone health, but they do not impact the metastases themselves and do not improve survival.
SAN ANTONIO – Since overexpression of the HER2/Erbb2 receptor was first described as a feature of some breast cancer in 1987, the overexpression has been turned from a negative to a positive predictive factor by the efforts of first academic researchers and then the biopharmaceutical industry.
Thyroid hormone (TH) activity was beneficial for resolving pulmonary fibrosis, or scarring of the lung, in mouse models of the disease, researchers from Yale University have reported. Pulmonary fibrosis can be the result of lung injury, but can also occur for unknown reasons, a condition known as idiopathic pulmonary fibrosis (IPF) that has been increasing in incidence and has a median survival time of three years from diagnosis.
SAN ANTONIO – Since overexpression of the HER2/Erbb2 receptor was first described as a feature of some breast cancer in 1987, the overexpression has been turned from a negative to a positive predictive factor by the efforts of first academic researchers and then the biopharmaceutical industry.
SAN ANTONIO – One of the most anticipated presentations on the first day of the 2017 San Antonio Breast Cancer Symposium (SABCS) was the B-47 study, which investigated the use of adjuvant Herceptin (trastuzumab, Roche Holding AG) in patients with low HER2 expression.
